RxDoctor Payments Data

Lance Taylor, MD

Gastroenterology · Albuquerque, NMNPI 1568501583

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.6% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 43.9% of the total. 2025 is the largest year on record at $458, more than ten times the $15 reported in 2019. That places this record below the midpoint for gastroenterology clinicians in NM, where the typical reported total is $1,418.

$1,384in general payments, 2019–2025

Across 76 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$608
  • Johnson & Johnson$319
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$166
  • Bristol Myers Squibb$53
  • Phathom Pharmaceuticals, Inc.$43
  • Madrigal Pharmaceuticals$35
  • plus $159 from 7 others

What the payments were for

  • Food & beverage$1,33897%
  • Education$473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,384 in reported general payments places this provider in the 45th percentile of 81 gastroenterology providers in New Mexico.

See all gastroenterology providers in New Mexico

Medicare billing

Part B allowed, 2024
$125,353
Medicare patients
380
Services billed
3,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase59$106,451
XifaxanRifaximin22$83,124
LinzessLinaclotide11$7,990
Omeprazole513$7,411
Mesalamine ErMesalamine25$4,803
Mesalamine13$2,702
Budesonide DrBudesonide20$1,947
Balsalazide Disodium18$1,681
Cholestyramine LightCholestyramine16$1,518
Famotidine62$1,403
Esomeprazole Magnesium27$1,162
Pantoprazole Sodium58$962
Lactulose21$621
Lansoprazole17$525
Dicyclomine Hcl15$478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$608$114,44270 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$166$83,12422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 81 gastroenterology providers in New Mexico.

Other gastroenterology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →